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Summanr We previously reported that the expression on the primary' tumour of the antigen CaMBr8 was
related to a short survival. attributable either to higher tumour aggressiveness or a poor response to
oophorectomy.
To further venrfy the CaMBr8 prognostic value. we analysed retrospectively 862 breast cancer patients with
a 19 year follow-up. In this series. CaMBr8 expression was found to be associated to some negative prognostic
factors (premenopausal status, lymphnode invasion, a high number of mitosis and HER-2 neu oncoprotein
expression). but had no influence on the patients' survival. Direct association with a poor prognosis was only
evident in patients with lobular or mixed breast carcinoma, which however represent only a small fraction of
the total breast cancers.
Another possibility was that CaMBr8 could identify a subgroup of patients which did not respond to
hormone therapy. To verify this hypothesis we evaluated on a second series of 116 patients the relationship
between CaMBr8 expression and hormone-receptor levels. A negative association emerged which was also
observed in vitro in the human breast cancer line MCF-7 treated with Sodium ButvTate. a differentiation
inducer. which reduced hormone-receptor levels and increased CaMBr8 expression.
In conclusion. the longer survival of CaMBr8 negative tumour patients observed in the initial study. wvas
probably related to a better response to oophorectomy. due to the hormone-receptor level of their tumours.
Breast cancer is a widely diffused disease and one of the most
common forms of cancer in women. It shows a marked
heterogeneity in its clinical and biological behaviour: among
patients submitted to radical treatment. about 50% present
local recurrences or develop distant metastases. Therefore. a
number of efforts have been made to identify prognostic
factors which can predict the course of the disease. Besides
traditional indicators such as primary tumour size. his-
tological grading and nodal status (McGuire et al.. 1990:
Fisher et al.. 1983). other factors such as cellular kinetics
(Silvestrini et al.. 1989: Silvestrini et al.. 1990: Clark et al..
1989). hormone-receptor levels (McGuire et al.. 1986: Chev-
allier et al.. 1988: Kinsel et al.. 1989). oncogene expression
(Slamon et al.. 1989: Tandon et al.. 1989: Paik et al.. 1990)
and expression of some tumour-associated antigens recog-
nised by monoclonal antibodies (Wilkinson et al.. 1984: Ellis
et al.. 1985). were found to correlate with the prognosis.
None of them. however. are entirely dependable. and the
identification of other more reliable factors is therefore being
pursued.
We previously reported that the expression on the primary
tumour of the antigen CaMBr8. recognised by the anti-breast
cancer monoclonal antibody MBr8. was both related to a
higher tumour aggressiveness (Colnaghi et al.. 1987: Colnaghi
et al.. 1988) and a poor response to oophorectomy (Cascinelli
et al.. 1988).
The aims of the present work were:
(1) To evaluate on a larger series of breast cancer patients
the prognostic value of CaMBr8 by analysing both its
association with some well-known prognostic factors and its
influence on patients' surVival.
(2) To verify CaMBr8 ability in identifying a subgroup of
breast cancer patients which does not respond to hormone
therapy by analysing the relationship between CaMBr8 ex-
pression and hormone-receptor level in a second series of
breast cancer patients and in an in *itro svstem.
Materials and methods
Patients
A first retrospective series of 862 consecutive patients with
operable breast cancer. submitted to radical or modified
radical mastectomy at this Institute from Januarn 1968 to
December 1971. was evaluated: the median follow-up was 19
years. Patients did not receive any adjuvant therapy and were
homogeneously treated at relapse.
The analysis of the clinical and histopathological para-
meters examined in this study has been reported elsewhere
(Rilke et al.. 1991).
A second prospective series of 116 consecutive patients
with primary carcinoma of the breast was used to evaluate
both CaMBr8 expression and hormone-receptor levels. The
patients were submitted to modified radical mastectomy or to
quadrantectomy. followed by radiotherapy. at this Institute
in 1985. They are now in follow-up.
The hormone-receptor levels were determined by the dex-
tran-coated charcoal (DCC) method. as previously described
(Di Fronzo et al.. 1986). The chosen cut-off values for oest-
rogen and progesterone receptors were respectively 10 and
25 fmol mg-' of protein.
Immunohistochemistrv
The monoclonal antibody MBr8. of IgM isotype. was raised
against breast carcinoma and its immunohistochemical char-
acterisation has been reported elsewhere (Colnaghi et al..
1987. Colnaghi et al.. 1988).
The reactivity of MBr8 (ascitic fluid diluted 1:100 or
purified antibody 10;ggml-') was evaluated on histological
sections of primary tumours by immunoperoxidase (IPX)
tests (first study) or on both frozen and paraffin-embedded
sections by both IPX and immunoflorescence (IF) tests
(second study).
Correspondence: MI. Colnaghi. Expenrmental Oncology E. Istituto
Nazionale Tumonr. Via Venezian 1. 20133 Milan. Italv.
2Present address: Division of Medical Oncology. Medical School II.
University of Naples Via S. Pansini 5. 80131 Napoli. Italy.
Received 16 May 1991: and in revised form 28 October 1991.
(E) Macmillan 11'ress Ltd.. 1991- Br. J. Cancer (1992). 65, 466-470BIOLOGICAL SIGNIFICANCE OF CaMBr8 ON BREAST CARCINOMA 467
The reactivity of the anti-HER-2 neu protein polyclonal
serum (diluted 1:500). provided by Dr Slamon (UCLA. Los
Angeles. CA). was evaluated on histological sections of
primary tumours by IPX tests.
Immunologic tests were carried out as previously descnrbed
(Menard et al.. 1983: Mariani-Costantini et al.. 1984). The
cases were considered positive if more than 10% of the
epithelial cells of the observed sample strongly stained.
Statistical analysis
The degree of association of CaMBr8 expression with the
well-known prognostic factors for breast cancer was studied
by resorting to the contingency table analysis and by looking
at the results of chi-square calculation: the patients' age and
histological grading were evaluated with a chi-square for
trend test.
Survival was defined from the date of diagnosis to the date
of death. and was analysed by the product-limit survival
curve method and by looking at the results fo the Log-rank
test. The overall cause of death was evaluated as either due
to breast cancer or to other causes.
The relapse-free survival data are not reported since they
coincide with the overall survival due to the very long
median exposition time (nearly 20 years).
In vitro study
The human breast cancer line MCF-7. obtained from the
American Type Culture Collection (Rockville. MD). was
maintained as a monolayer culture in RPMI 1640 medium
supplemented with 10% foetal calf serum. 2 mM L-glutamine.
penicillin 100 units ml1. streptomycin 00 zg ml (culture
medium). Treatment of the cells was carried out in culture
medium supplemented with 1.5-3 mM sodium butyrate (SIG-
MA) 1 day after plating. Two days after the addition of
sodium butyrate the cells were harvested with 0.05% trypsin
and 0.02% EDTA, pelleted. resu-spended in medium and
stored overnight at 4'C.
CaMBr8 expression was evaluated by IF carried out on the
cells in suspension with MBr8 ascitic fluid diluted 1:100. The
percentage of positive cells and fluorescence intensity were
evaluated by an EPICS flow cytometer (EPICS. Coulter Elec-
tronics. Hialeah. FL).
Hormone-receptor expression was determined by IPX tests
carried out according to the instructions of the Abbott kit
(Abbott Labs.. Chicago. IL) with the following
modifications: (1) cell fixation in paraformaldehyde 4% in
phosphate buffer 0.1 M pH 7.4 for Omin; (2) use of the
avidin-biotin peroxidase complex method (ABC kit. Vector.
Burlinghame, CA) instead of the peroxidase-anti-peroxidase
method.
Growth in semisolid agar was performed essentially as
described (Kim et al.. 1980). Monolayers of the cells, cul-
tured for 2 days in the presence of 1.5 or 3 mm sodium
butyrate, were harvested with trypsin, suspended in agar
medium without the inducer and seeded in a six-well dish
(about 1.500 cells well; two wells for each sample): alterna-
tively the cells, routinely cultured in the absence of the
inducer, after the treatment with trypsin, were suspended in
agar medium containing 1.5 or 3mM sodium butyrate and
were seeded as previously described. The colonies were
counted under a light microscope 4 weeks later.
Results
Multi-parametric retrospective study}
In order to evaluate the relationship between CaMBr8 ex-
pression and some parameters already known to have a
prognostic value, we analysed 862 primary breast carcinomas
from consecutive patients with a median follow-up of 19
years.
In this series 58% of the tumours were found to be MBr8-
positive. The results are reported in Table I: CaMBr8 expres-
sion was directly associated with premenopausal status
(P<0.001). lymphnode invasion (P<0.01). a high number
of mitosis (P<0.01) and HER-2 neu oncoprotein expression
(P<0.01). No significant relationship was found between
CaMBr8 expression and tumour size. tumour histotype and
tumour grading. even though a trend could be observed
towards a higher expression in poorly differentiated tumours.
All the clinical and pathological parameters analysed. except
for the tumour histotype. have in the present series a
significant impact on survival (Rilke et al.. 1991). Survival
analysis showed that CaMBr8 expression did not correlate
with the 19-year overall survival (Figure la): patients whose
tumours were MBr8-positive showed the same survival as
patients with MBr8-negative tumours. By stratifying each of
the analysed parameters. a statistically significant relationship
only emerged between CaMBr8 expression and a worse prog-
nosis in patients with lobular or mixed carcinoma of the
breast (Figure 1b). No association was found instead in
patients with ductal carcinomas (Figure 1c). which represent
in this series 85% of the total.
Association between CaAMBr8 expression and hormone-receptor
levels
To further investigate the relationship between CaMBr8 ex-
pression on primary tumours and the response to hormonal
therapy. CaMBr8 expression was evaluated in relation to
hormone-receptor levels in a prospective study including 116
patients with ductal or lobular primarv carcinoma of the
breast. In this series 70% of the tumours were found to be
MBr8-positive. 71% expressed oestrogen receptors and 70%
progesterone receptors. As shown in Table II CaMBr8 was
inversely related to the expression of both hormone recep-
tors. This correlation was statistically significant (P<0.01).
Association between CaMVBr8 expression and hormone-receptor
levels in vitro
To study the relationship between CaMBr8 and hormone
receptors in an in vitro system we used the human breast
Table I Retrospective study: expression of CaMBr8 according to
climical and pathological parameters
No. ofCaMBr8-positive
Clinical parameters cases total 0O P
Age
<40 63 94 67
41-49 151 229 66
50-54 51 87 59 <0.01
55-59 83 147 56
>60 154 305 50
Menopausal Status
pre 194 290 67 <0-001
post 272 513 53
Lymphnode invasion
N- 200380 53 <0.01
N+ 289 458 63
Tumour size
<2cm 271 460 59 n.s.
>2cm 147248 59
Grading
GI 45 81 56
G2 140 241 58 n.s.
G3 206 337 61
Histotype
Ductal 428 732 58
Mixed Lobular 71 125 57 n.s.
N' Mitosis
< 1 114 219 52 <0.01
>1 351 567 62
Neu protein expression
Neg 369 666 55 <0.01
Pos 133,196 68468 P. FACHERIS et al.
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1984a) sodium butyrate reduced in a dose-dependent manner
a q the cell growth rate and induced evident morphological alter-
ations such as cell enlargement and emission of cytoplasmic
processes. The used dosage of the inducer had little or no
effect on cell viability, as assessed by Trypan Blue exclusion.
Moreover, sodium butyrate suppressed the anchorage-inde-
pendent growth: when the cells were cultured for 2 days in
the presence of the inducer before cloning, the number of
colonies decreased from 100 (control medium) to 52 (sodium
butyrate 1.5 mM) and to three colonies (sodium butyrate
3 mM). Moreover, when the cells were cloned in the presence
of the inducer they did not form colonies even at the lower
15 20 concentration of sodium butyrate.
In the presence of sodium butyrate CaMBr8 expression on
the cultured cells increased in a dose-dependent manner. In
Figure 2 it can be observed that only 30% of the control cells
b expressed CaMBr8 with a low fluorescence intensity (average
F.I. 75.4). If the cells were cultured for 2 days with sodium
butyrate 1.5 mM the percentage of positive cells increased to
60% and two cell populations could be distinguished, one
with low and another with high MBr8 F.I. At the 3 mM
concentration the positive cells were about 80% and the low
F.I. population switched to the higher one (average F.I.
144.2).
The simultaneous evaluation of CaMBr8 and hormone-
receptor expression (Table III) showed that sodium butyrate
induced an increase in the MBr8 reactivitv which corres-
15 20 ponded to a reduced oestrogen and progesterone receptor
expression. Both events were dose-dependent.
C Discaion
In a small but highly selected group of breast cancer patients.
treated with oophorectomy at their first relapse. we reported
that the presence on the primary tumour of the antigen
CaMBr8. recognised by the anti-breast cancer monoclonal
antibody MBr8, was associated with a short survival (Col-
naghi et al.. 1987: Colnaghi et al.. 1988) and a worse res-
ponse to oophorectomy (Cascinelli et al.. 1988). This either
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Figure 1 Overall survival according to CaMBr8 expression in
patients with operable breast cancer. a. Total carcinomas: MBr8
neg. 360. MBr8 pos. 502: b. Lobular and mixed carcinomas:
MBr8 neg. 54. MBr8 pos. 71: c. Ductal carcinomas: MBr8 neg.
304. MBr8 pos. 428. MBr8 neg. S: MBr8 pos. +
Table 11 Relationship between CaMBr8 expression and
hormone-receptors in 116 pnrmarv breast carcinomasa
No. of CaAfBr8 positive
Hormone receptor cases total 0 P
Oestrogen receptor
POS 6294 66 <0.01
NEG 2022 91
Progesterone receptor
POS 54 83 65
NEG 27 3_2 84 <0
aCaMBr8 and hormone-receptor expression was esaluated by IF or
IPX tests and DCC method respectivelv.
cancer line MCF-7. which expresses the CaMBr8 antigen in
about 30-40% of the cells. and the cell differentiation
inducer sodium butyrate, which has previously been reported
to reduce oestrogen-receptor levels in this cell line (Stevens et
al.. 1984).
At first we evaluated the effects of sodium butvrate on
MCF-7 cells. In agreement with previous data (Abe & Kufe.
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Figue 2 Effect of sodium butyrate on CaMBr8 expression in
MCF-7 cells. The cells were cultured for 2 days in RPMI + FCS
10% with or without 1.5-3mM sodium butyrate. CaMBr8 ex-
pression was evaluated by IF. The intensity of the fluorescence
was recorded on a logarithmic scale as arbitrary units (a.u.). The
solid line within each histogram represents the position of the
gate used to evaluate the percentage of positive cells and their
fluorescence intensity. a. Control: b. sodium butyrate 1.5 mM: c.
sodium butyrate 3 mM.
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Table III Effect ofsodium butyrate on the expression ofCaMBr8 and
hormone-receptors in MCF-7 cellsa
Sodiwn butnrate
Marker (mwJ % cfpositive cells
CaMBr8 0 40
1.5 56
3 75
Oestrogen receptor 0 40
1.5 10
3 <1
Progesterone receptor 0 20
1.5 10
3 <1
'The cells were cultured for 2 days in RPMI + FCS 100o with or
without 1.5-3 mm sodium butyrate. CaMBr8 and hormone-receptor
expression was evaluated by IF and IPX tests respectively
suggests that CaMBr8 may act as a prognostic factor for
breast cancer or that it may identify a subgroup of patients
which does not respond to hormone therapy.
In order to verify these hypotheses two studies were car-
ried out: a retrospective one to evaluate the CaMBr8
influence on the patients' survival and its association with
some well-known prognostic factors and a prospective one to
analyse the relationship between MBr8 reactivity and hor-
mone-receptor levels. which could not have been evaluated in
the first study.
In both studies MBr8 labelled a relevant percentage of
primary breast tumours. However. in the first patients' series
the percentage of MBr8-positive tumours was lower than in
the second one. This difference could not be attributed to a
difference in sample fixation since in the prospective study
the evaluation on both histological and frozen sections
showed similar MBr8 reactivity. The lower MBr8 reactivity
observed in the retrospective study could either be explained
by changes in the tumour phenotype during the 20-year lapse
between the two patients' series and or by structural altera-
tions of some CaMBr8 molecules. due to the long storage
time of the tumour surgical specimens or to the type of
fixative used.
CaMBr8 expression. despite its statistically significant as-
sociation with some well-known prognostic factors (premeno-
pausal status. lymphnode invasion. a high number of mitosis.
mitosis. HER-2 neu oncoprotein expression and low hor-
mone-receptor levels), does not seem to have any prognostic
significance. at least for ductal carcinoma, which is the most
frequent breast cancer histotype.
A statistically significant relationship between CaMBr8
expression and a worse prognosis was however observed in
patients with lobular or mixed breast carcinoma. This could
have a particular significance since CaMBr8 in the normal
mammary gland is preferentially expressed on the lobules
(Perrone et al.. 1990). Moreover, the difference in the prog-
nostic impact of CaMBr8 between lobular and ductal breast
cancer could be attributed to their different clinical pattern of
metastases (Dixon et al.. 1991). In keeping with this hypo-
thesis. it was recently reported (Dejana et al.. 1991) that the
monoclonal antibody MBr8 specifically inhibits the adhesion
of the colon carcinoma cell line HT29 to endothelial cells
activated with IL-1 and prevents the same cells from being
retained in the lungs of mice treated with IL-1. The carbo-
hydrate structure recognised by MBr8 could therefore play
an important role in the metastatisation process of some
cancer cells. Further studies on a larger number of cases are
now required to understand the significance of CaMBr8 ex-
pression in lobular and mixed breast carcinomas which crnlv
represent 10% of breast cancers.
The lack of prognostic value of CaMBr8 expression. in
spite of its statistically significant association with parameters
which have been reported to have a significant impact on
prognosis. could be explained by the fact that the prognostic
power for each factor is not absolute. The different predicting
strength of each parameter and a lack of a complete overlap-
ping of the two could therefore be responsible for the discor-
dant results. Similar findings have been obtained when in the
same series of patients other parameters were compared
(Rilke et al.. 1991).
These results indicate that the simple association with
known prognostic indicators is not sufficient to extrapolate a
predicting value for a new factor in evaluation. The longer
survival of MBr8-negative tumour patients (Cascinelli et al..
1988) was probably related to a better response to oophorec-
tomy, due to the hormone-receptor levels of their tumours.
To further study the biological significance of CaMBr8
expression we chose an in vitro model in which hormone-
receptor levels and cell malignancy were not associated and
could be considered as independent parameters. This model
consisted of the treatment of the breast cancer cell line
MCF-7 with sodium butyrate. a potent inducer of cell
differentiation (Collins et al.. 1978; Kim et al.. 1980: Abe &
Kufe. 1984a & b: Langdon et al.. 1988). which reduces
progesterone and oestrogen-receptor levels in human breast
cancer lines (HorWitz et al.. 1982: Stevens et al.. 1984). In
keeping with the results of the prospective study. CaMBr8
expression in MCF-7 cells treated with sodium butyrate was
negatively associated with hormone receptors. However. no
correlation was found with the in vitro growth characteristics
associated with malignancy.
In conclusion, also in view of the prognostic significance
for a restricted group of breast cancer patients. it would be
interesting to further investigate the biological significance of
the antigen CaMBr8 and the nature of its negative associa-
tion with hormone receptors.
We thank Ms M. Hatton and Ms L. Mameli for manuscript prepara-
tion and Mr M. Azzini for the photographic reproductions.
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